PND19 - Impact of Ocrelizumab Vs. Interferon Beta-1a In Delaying The Deterioration Of Patients' Daily Functions and Associated Costs In Relapsing-Remitting Multiple Sclerosis
| Autor: | Yang, H, Duchesneau, ED, Guerin, A, Ma, E, Thomas, NP |
|---|---|
| Zdroj: | In Value in Health October-November 2017 20(9):A721-A721 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect